What are the recommended intravenous dosing schedules, premedication, and monitoring for paclitaxel in adult patients with solid tumors such as breast, ovarian, and non‑small cell lung cancer?

Paclitaxel Dosing, Premedication, and Monitoring

Premedication (Critical for All Patients)

All patients must receive premedication prior to paclitaxel administration to prevent severe hypersensitivity reactions 1. The standard premedication regimen consists of:

• Dexamethasone 20 mg PO at 12 hours and 6 hours before paclitaxel
• Diphenhydramine 50 mg IV (or equivalent) 30-60 minutes before paclitaxel
• H2-antagonist: Cimetidine 300 mg IV OR ranitidine 50 mg IV, 30-60 minutes before paclitaxel

Exception for AIDS-related Kaposi's sarcoma: Reduce dexamethasone to 10 mg PO (instead of 20 mg) due to immunosuppression 1.

---

Recommended Dosing Schedules by Tumor Type

Ovarian Cancer

For previously untreated patients (Category 1 recommendations) 2, 3, 2:

1. Standard 3-hour regimen: Paclitaxel 175 mg/m² IV over 3 hours, followed by carboplatin AUC 5-7.5 IV over 1 hour on day 1, every 3 weeks for 6 cycles

2. 24-hour regimen: Paclitaxel 135 mg/m² IV continuous infusion over 24 hours on day 1, followed by cisplatin 75 mg/m² IV on day 1, every 3 weeks

3. Dose-dense weekly regimen: Paclitaxel 80 mg/m² IV over 1 hour on days 1,8, and 15, plus carboplatin AUC 6 IV on day 1, every 3 weeks for 6 cycles

4. Weekly alternative: Paclitaxel 60 mg/m² IV over 1 hour followed by carboplatin AUC 2 IV, weekly for 18 weeks 4

For previously treated patients: Paclitaxel 135-175 mg/m² IV over 3 hours every 3 weeks 1.

For optimally debulked stage III disease (Category 1): Consider intraperitoneal regimen - Paclitaxel 135 mg/m² IV over 3 or 24 hours day 1; cisplatin 75-100 mg/m² IP day 2; paclitaxel 60 mg/m² IP day 8, every 3 weeks for 6 cycles 2, 5.

Breast Cancer

Adjuvant treatment for node-positive disease 1:

• Paclitaxel 175 mg/m² IV over 3 hours every 3 weeks for 4 courses, administered sequentially after doxorubicin-containing chemotherapy

Metastatic disease 6:

• Standard: Paclitaxel 175 mg/m² IV over 3 hours every 3 weeks
• Weekly: Paclitaxel 80 mg/m² IV weekly
• Dose-dense: Paclitaxel with doxorubicin/cyclophosphamide every 2 weeks 7

Albumin-bound paclitaxel alternatives 6:

• 100-150 mg/m² IV on days 1,8,15 every 28 days
• 260 mg/m² IV every 21 days

Non-Small Cell Lung Cancer

First-line treatment 1:

• Paclitaxel 135 mg/m² IV over 24 hours on day 1, followed by cisplatin 75 mg/m² IV, every 3 weeks

Alternative schedules show similar efficacy with 3-hour infusions at 175-225 mg/m² 8.

---

Monitoring Requirements

Before Each Cycle

Do not administer paclitaxel unless 1:

• Solid tumors: Neutrophil count ≥1,500 cells/mm³ AND platelet count ≥100,000 cells/mm³
• AIDS-related Kaposi's sarcoma: Neutrophil count ≥1,000 cells/mm³

Dose Modifications for Toxicity

Reduce dose by 20% for subsequent courses if 1:

• Severe neutropenia (neutrophils <500 cells/mm³ for ≥1 week)
• Severe peripheral neuropathy

Hepatic Impairment Adjustments

For 3-hour infusion (baseline dose 175 mg/m²) 1:

• Transaminases <10× ULN AND bilirubin ≤1.25× ULN: 175 mg/m²
• Transaminases <10× ULN AND bilirubin 1.26-2.0× ULN: 135 mg/m²
• Transaminases <10× ULN AND bilirubin 2.01-5.0× ULN: 90 mg/m²
• Transaminases ≥10× ULN OR bilirubin >5.0× ULN: Not recommended

For 24-hour infusion (baseline dose 135 mg/m²) 1:

• Transaminases <2× ULN AND bilirubin ≤1.5 mg/dL: 135 mg/m²
• Transaminases 2-<10× ULN AND bilirubin ≤1.5 mg/dL: 100 mg/m²
• Transaminases <10× ULN AND bilirubin 1.6-7.5 mg/dL: 50 mg/m²
• Transaminases ≥10× ULN OR bilirubin >7.5 mg/dL: Not recommended

---

Key Toxicities to Monitor

Most common dose-limiting toxicity: Myelosuppression (neutropenia) 1

Other significant toxicities:

• Peripheral neuropathy (increases with cumulative dose and infusion duration)
• Myalgia/arthralgia syndrome
• Hypersensitivity reactions (occur almost exclusively during first exposure) 9
• Alopecia (universal)

Regimen-specific toxicities 2:

• Dose-dense paclitaxel: Increased anemia
• IP paclitaxel/cisplatin: Leukopenia, infection, fatigue, renal toxicity, abdominal discomfort, neurotoxicity

---

Administration Considerations

Avoid PVC equipment: Use glass, polypropylene bottles or polyolefin bags with polyethylene-lined administration sets to minimize DEHP exposure 1.

Infusion duration matters: Shorter infusions (1-3 hours) are associated with less myelosuppression but potentially more neuropathy and myalgia compared to 24-hour infusions 1.